|
|
 |
|
Viewing report
|
|
|
|
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Datamonitor, Nov 2007, Pages: 162
With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing.
However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.
Scope
Overview of drivers and resistors of licensing deals, with recommendations and case study analysis of how companies can optimize the licensing process
Examination of how to successfully navigate the licensing process, with analysis of how companies are looking to modernize their licensing strategies
Analysis of key product deals during 2005-06, analyzing trends for in-licensing, co-development, out-licensing and marketing & promotion deals
Assessment of drug discovery deals and technology deals, made by the top 20 pharmaceutical companies during 2005-06
Highlights
The constant demand for late-stage product candidates has led to spiraling deal costs. Therefore companies are now looking to in-license earlier-stage compounds, demonstrated by the recent resurgence in preclinical and Phase I licensing deals made by the top 20 pharmaceutical companies. Companies facing patent expiries of key revenue drivers between 2006-12 have in-licensed products to counteract the ensuing sales erosion. However, this tactic is not expected produce a positive growth in the short term for all companies, although it will at least offset part of their revenue deficit. During 2005-06, Novartis was the leading dealmaker, followed by Bayer-Schering, Roche, and J&J, with the top six companies responsible for 50% of all deals made by the leading 20 companies.
Reasons to Purchase
Understand the opportunities and threats companies face when licensing their products, and the resultant strategies some companies are employing
Identify suitable Pharma to target when considering licensing partners for your technologies and products
Benchmark the success of your licensing strategy in order to improve future deal making success
Customers who bought this item also bought
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
Guide to Valuation of Pharmaceutical Licensing Deals
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Licensing Strategies: Benchmarking Analysis of the Top 20 Pharmaceutical Companies
Bio-Device Licensing: Strategies for Success
Effective Licensing & Commercialisation of Drug Delivery Systems 2006
Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals
Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management
Mid Pharma Sector: In-licensing and Other Externalization Strategies
Valuing and Structuring Pharmaceutical Licensing Agreements
The Pharmaceutical Licensing Outlook: A Strategic Guide To Effective Deal-Making And Profitable Partnerships
The Licensing Agreement in Pharmaceutical Business Development: 3rd edition
|
|
|
|
